GLP-1 heart-health headlines: what does a 20% reduction mean?

Begin with the question the trial asked

SELECT enrolled 17,604 adults aged at least 45 with established cardiovascular disease, BMI of at least 27 and no history of diabetes. They were randomly assigned to weekly injectable semaglutide or placebo. Average follow-up was about 40 months.

FDA’s approval announcement explains that both groups also received usual medical care, including management of blood pressure and cholesterol, and lifestyle counseling. The trial tested an additional treatment within that care, not a replacement for the rest of a heart-health plan.

“Heart health” was a specific set of events

The primary trial outcome combined cardiovascular death, nonfatal heart attack and nonfatal stroke, measuring time to the first such event. Researchers call this a composite endpoint. It is narrower than a claim about every possible heart condition.

When a headline compresses several outcomes into one phrase, unpack it. A reduction in the combined outcome does not establish the same-sized reduction in each component. It also does not tell you that someone’s cholesterol, symptoms or exercise tolerance improved by that percentage.

The headline and the event percentages answer different questions

The paper reported a hazard ratio of 0.80, the basis for the 20% relative-reduction headline. A hazard ratio compares how events occur over follow-up; it is not a percentage-point subtraction.

FDA reports that a primary cardiovascular event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. Subtracting those reported proportions gives an absolute difference of 1.5 percentage points. That calculation describes the observed group proportions, not the time-to-event analysis behind the hazard ratio.

For a scale illustration, those rounded proportions correspond to roughly 65 versus 80 people per 1,000 over the study follow-up. They do not describe an annual rate or guarantee that a particular person will avoid an event. Keep the population, time period and type of calculation attached to the number.

A benefit finding still needs a benefit-risk discussion

More participants receiving semaglutide stopped the trial product because of adverse events than those receiving placebo, according to the original report. A cardiovascular benefit does not remove tolerability and safety from the decision.

The current Wegovy prescribing information lists contraindications, a boxed thyroid-tumor warning and other precautions. It also distinguishes formulations and approved uses. Use current labeling for a treatment discussion; an older news release is evidence of what was announced on its publication date, not a complete current medication guide.

Ask whether the evidence answers your own question

A person researching prevention before any diagnosed cardiovascular disease is asking a different question from someone who already has it. A paper’s size does not erase its entry criteria. Ask your clinician which evidence matches your history and the product being considered.

MedlinePlus recommends checking who participated, how long research lasted, what type of study it was and who funded it. SELECT was funded by Novo Nordisk, as disclosed in the original paper. Funding is information to weigh with methods and results; it should be visible to the reader.

• Which event or health outcome are we trying to reduce?
• Does the proposed product have evidence and an approved use relevant to that goal?
• How would treatment fit with my existing cardiovascular medicines and follow-up?
• What benefits, side effects and alternatives should we review together?

Keep the evidence boundary visible when researching CoreAge Rx

CoreAge Rx describes compounded semaglutide and tirzepatide offerings on its official site. SELECT was not a trial of those preparations or of CoreAge Rx patients. The service’s ingredient names do not transfer the trial’s cardiovascular result to its offerings.

FDA explains that compounded drugs are not approved and do not undergo its premarket review for safety, effectiveness and quality. If cardiovascular risk is why you are seeking care, discuss the appropriate product and coordination with your existing clinician before interpreting a service offer.

Our CoreAge Rx service review provides program context. The official intake instructions identify health history and current medicines as information for provider review. Our medical-review-label guide helps you assess the articles you read along the way.

Common questions

Keep researching

• Understand a medical-review label
• Read the CoreAge Rx service review
• Explore more medical reporting